These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21979906)

  • 21. Risk of dying from early prostate cancer is low regardless of treatment, study finds.
    White C
    BMJ; 2016 Sep; 354():i4984. PubMed ID: 27633860
    [No Abstract]   [Full Text] [Related]  

  • 22. Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
    Schriefer P; Steurer S; Huland H; Graefen M
    J Clin Oncol; 2012 Nov; 30(32):e341-4. PubMed ID: 23032622
    [No Abstract]   [Full Text] [Related]  

  • 23. Diagnostic challenges of clonal heterogeneity in prostate cancer.
    Haffner MC; De Marzo AM; Yegnasubramanian S; Epstein JI; Carter HB
    J Clin Oncol; 2015 Mar; 33(7):e38-40. PubMed ID: 24638011
    [No Abstract]   [Full Text] [Related]  

  • 24. ['Men are not dying with, but from prostate cancer'].
    Stief C
    MMW Fortschr Med; 2014 Dec; 156(21-22):66. PubMed ID: 25608413
    [No Abstract]   [Full Text] [Related]  

  • 25. Prostate cancer: detection, staging, and treatment of localized disease.
    Potter SR; Partin AW
    Semin Roentgenol; 1999 Oct; 34(4):269-83. PubMed ID: 10553603
    [No Abstract]   [Full Text] [Related]  

  • 26. Men considering a hypothetical treatment for prostate cancer: a comparison to patients.
    Van Manen L; Feldman-Stewart D; Brundage MD
    Patient Educ Couns; 2006 Apr; 61(1):33-42. PubMed ID: 16257170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [PSA 2010--the beginning of a new era in early detection of prostate cancer].
    Börgermann C; Sieverding M; Fornara P; Graefen M; Hammerer P; Semjonow A; Schröder F; Rübben H
    Urologe A; 2006 Sep; 45 Suppl 4():127-33. PubMed ID: 16941115
    [No Abstract]   [Full Text] [Related]  

  • 28. [Early diagnosis of prostate cancer].
    Hocaoglu Y; Seitz M; Stief CG; Bastian PJ
    MMW Fortschr Med; 2012 Jan; 154(1):43-6. PubMed ID: 22642003
    [No Abstract]   [Full Text] [Related]  

  • 29. Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey.
    Hall JD; Boyd JC; Lippert MC; Theodorescu D
    Urology; 2003 Feb; 61(2):402-7. PubMed ID: 12597956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACR Appropriateness Criteria
    ; Froemming AT; Verma S; Eberhardt SC; Oto A; Alexander LF; Allen BC; Coakley FV; Davis BJ; Fulgham PF; Hosseinzadeh K; Porter C; Sahni VA; Schuster DM; Showalter TN; Venkatesan AM; Wang CL; Remer EM
    J Am Coll Radiol; 2018 May; 15(5S):S132-S149. PubMed ID: 29724417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer: essays on decision making.
    Kissil D; Lippman AJ
    N J Med; 1996 May; 93(5):57-60. PubMed ID: 8871506
    [No Abstract]   [Full Text] [Related]  

  • 32. Impact of prostate-specific antigen density in benign prostatic hyperplasia and prostate carcinoma. Preliminary results.
    Akdaş A; Dillioğlugil O; Cevik I; Ilker Y
    Eur Urol; 1994; 25(4):299-303; discussion 304. PubMed ID: 7519992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Focal therapy of prostate cancer in Germany].
    Apfelbeck M; Herlemann A; Stief CG; Gratzke C
    Urologe A; 2016 May; 55(5):584-92. PubMed ID: 27142799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of an online support group on patients׳ treatment decisions for localized prostate cancer: An online survey.
    Huber J; Maatz P; Muck T; Keck B; Friederich HC; Herzog W; Ihrig A
    Urol Oncol; 2017 Feb; 35(2):37.e19-37.e28. PubMed ID: 27810256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moving towards shared decision making in prostate cancer screening.
    Hoffman RM; Helitzer DL
    J Gen Intern Med; 2007 Jul; 22(7):1056-7. PubMed ID: 17364242
    [No Abstract]   [Full Text] [Related]  

  • 36. [Detection of prostate cancer. German guideline recommends opportunist screening].
    Arnheim K
    MMW Fortschr Med; 2010 Sep; 152(39):12-3. PubMed ID: 21058430
    [No Abstract]   [Full Text] [Related]  

  • 37. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.
    Ganz PA; Barry JM; Burke W; Col NF; Corso PS; Dodson E; Hammond ME; Kogan BA; Lynch CF; Newcomer L; Seifter EJ; Tooze JA; Viswanath K; Wessells H
    Ann Intern Med; 2012 Apr; 156(8):591-5. PubMed ID: 22351514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guideline of guidelines: prostate cancer screening.
    Loeb S
    BJU Int; 2014 Sep; 114(3):323-5. PubMed ID: 24981126
    [No Abstract]   [Full Text] [Related]  

  • 39. Prostate cancer: measuring PSA.
    Pezaro C; Woo HH; Davis ID
    Intern Med J; 2014 May; 44(5):433-40. PubMed ID: 24816306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD.
    Pacyna JE; Kim S; Yost K; Sedlacek H; Petereit D; Kaur J; Rapkin B; Grubb R; Paskett E; Chang GJ; Sloan J; Basch E; Major B; Novotny P; Taylor J; Buckner J; Parsons JK; Morris M; Tilburt JC
    BMC Cancer; 2018 Aug; 18(1):788. PubMed ID: 30081846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.